Between Jun News Today

1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There were fewer treatment-related and serious adverse events among patients in the PET-based group compared to the non-PET-based group. Evidence Rating Level: 1 (Excellent) Study Rundown: Human epidermal growth factor receptor 2-positive (HER2-positive) breast cancers are associated with a high risk of

1. The 30-day composite primary safety endpoint of > 40.5% was achieved for Trilogy TAVI. 2. 8% of patients who underwent Trilogy TAVI had passed at the 1-year follow-up. Evidence Rating Level: 1 (Excellent) Study Rundown: Surgery remains the primary intervention for native aortic regurgitation, but high-risk patients lack optimal alternatives. Traditional transcatheter heart valves

1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly higher rates of grade 3 or higher adverse events compared to the placebo-chemoradiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Pembrolizumab has demonstrated efficacy in advanced cervical cancer, prompting an investigation into its potential

1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across all intervention groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Diabetic macular oedema (DMO) leads to vision loss in 5% of patients with diabetes. Anti-vascular endothelial growth factor (anti-VEGF) medications, such as

1. The 3-month symptomatic venous thromboembolism rate was 0.7% in patients with TRiP(cast) score < 7 and not receiving anticoagulation. 2. There was no significant difference between the control and intervention phases regarding secondary outcomes. Evidence Rating Level: 1 (Excellent) Study Rundown: Venous thromboembolism (VTE) is a well-recognized potential complication resulting from orthopedic trauma and

1. Efficacy of spesolimab appeared to be dose-dependent with high-dose spesolimab leading to a significantly longer time to GPP flare-up versus placebo. 2. There were no treatment-related deaths or hypersensitivity reactions across groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Generalized pustular psoriasis (GPP) is a rare but chronic skin condition with a high morbidity.

1. Avacincaptad pegol significantly slowed geographic atrophy over 12 months. 2. Exudative macular neovascularization was comparable among treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Geographic atrophy is a severe form of age-related macular degeneration that can lead to irreversible vision loss. Currently, limited treatments exist. Avacincaptad pegol is a complement C5 inhibitor that

1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable among patients in either group. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatocellular carcinoma comprises a predominant portion of primary liver malignancies. Immunotherapy combined with anti-angiogenic treatment has shown promise in various advanced solid tumors,

1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR group experienced grade 3 immunological adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Standard treatment for early-stage inoperable non-small-cell lung cancer (NSCLC) includes stereotactic ablative radiotherapy (SABR). However, relapses remain common. Although immunotherapy may has

1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR group experienced grade 3 immunological adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Standard treatment for early-stage inoperable non-small-cell lung cancer (NSCLC) includes stereotactic ablative radiotherapy (SABR). However, relapses remain common. Although immunotherapy may